Please login to the form below
Prexton
This page shows the latest Prexton news and features for those working in and with pharma, biotech and healthcare.
Lundbeck bolts on migraine drug via $1.95bn deal to buy Alder
$1b purchase of Prexton Therapeutics and phase 2 Parkinson’s disease therapy foliglurax.
Latest news
-
Lundbeck snaps up Abide Therapeutics for $400m
agreed a $1.1bn deal last year to buy Prexton Therapeutics and its mid-stage Parkinson’s disease candidate foliglurax.
-
Lundbeck signs $1.1bn deal for Prexton and Parkinson’s drug
Lundbeck bolstered its R&D pipeline ahead of the weekend with a 900m ($1.1bn) deal to acquire Prexton Therapeutics and its mid-stage Parkinson’s disease (PD) candidate foliglurax. ... Prexton was set up in 2012 as a spin-out from Merck Serono’s R&D
-
Merck Serono completes move to Germany
the creation of Parkinson's disease-focused Prexton Therapeutics and the biomarker specialist Quartz Bio.
More from news
Approximately 1 fully matching, plus 3 partially matching documents found.
Latest Intelligence
-
Switzerland: a life sciences hub
For example, over the last five years, Lundbeck acquired Prexton Therapeutics, Agilent acquired Genohm and Boehringer Ingelheim acquired Amal Therapeutics, focused on cancer immunotherapy and therapeutic cancer vaccines.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Medical Writer, MRNA/ Covid 19, Medical Communications, UK
-
Highly competitive salary
- Country Manager, Healthcare Communications Agency, Germany
-
Highly competitive salary
- Scientific Strategy Lead, Medical Communications, UK
-
Highly competitive salary
- AstraZeneca and Innate Pharma to end study on immuno-oncology drug monalizumab
- AstraZeneca and MSD’s breast cancer drug Lynparza receives EC approval
- Regeneron terminates four clinical trials of its COVID-19 antibody cocktail REGEN-COV
- Roche’s Tecentriq demonstrates positive phase 3 results as a subcutaneous injection
- Gilead announces positive Biktarvy data for HIV and hepatitis B
- Janssen announces positive results supporting Rybrevant and lazertinib combination treatment for NSCLC
- Medscape Education Receives Joint Accreditation with Commendation to Deliver Continuing Education for Healthcare Providers
- Amgen acquires ChemoCentryx in $3.7bn cash deal
- Gilead Sciences set to acquire MiroBio in deal worth over $400m
- NHS England to roll out continuous glucose monitors to all those with type 1 diabetes
- Sanofi and Innovent Biologics to develop oncology drugs for patients in China
- WHO launches funding appeal for greater Horn of Africa prompted by food crisis
PMHub
Genesis Research
Genesis Research is an international HEOR and RWE research organization. A leader in evidence strategy, generation and communication, the company...
Latest intelligence
- Animation: Living With
- The journey from the patient's perspective...
- Achieving communication excellence by targeting the right channel at the right time
- By Danny Buckland...
- 6 trends shaping the future of personalized medicine
- Senior Consultant Leah Carlisle explores the key trends discussed at the 16th annual Personalized Medicine Conference, providing expert analysis and key recommendations for biopharmaceutical innovators....
